{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T19:21:59Z","timestamp":1784661719836,"version":"3.55.0"},"reference-count":30,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Otolaryngol Head Neck Surg"],"published-print":{"date-parts":[[2025,5,1]]},"abstract":"<jats:sec id=\"ab-ooi240113-4\"><jats:title>Importance<\/jats:title><jats:p>Despite the favorable prognosis for HPV\u2212positive oropharyngeal squamous cell carcinoma (HPV<jats:sup>+<\/jats:sup> OPSCC), efforts to de-escalate treatment intensity, while maintaining low recurrence and mortality rates, have proven challenging. Identifying appropriate prognostic factors remains elusive; however, the association of pretreatment circulating tumor tissue viral\u2212modified HPV (TTMV-HPV) DNA level with known characteristics of disease burden\u2014clinical staging, characteristics of pretreatment imaging, and aggressive histopathologic features of surgical specimen\u2014may offer insights that could shift treatment paradigms for HPV<jats:sup>+<\/jats:sup> OPSCC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240113-5\"><jats:title>Objective<\/jats:title><jats:p>To investigate the association of pretreatment TTMV-HPV DNA levels with clinical, radiologic, histopathologic, and outcome metrics in patients with HPV<jats:sup>+<\/jats:sup> OPSCC.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240113-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This cohort study of patients with HPV<jats:sup>+<\/jats:sup> OPSCC and positive test results for pretreatment TTMV-HPV DNA fragment levels used data from a single tertiary center from April 2020 to September 2023. TTMV-HPV DNA fragments levels were categorized into 3 cohorts: low (\u226499 fragments\/mL), moderate (100-999\/mL), and high (\u22651000\/mL).<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240113-7\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Association of clinical tumor (cT) and nodal (cN) staging with TTMV-HPV DNA fragment level. Secondary outcomes included the association between TTMV-HPV DNA fragment level and positive emission tomography\u2212computed tomography (PET-CT) characteristics as well as  histopathologic features of surgical specimen. The association of pretreatment fragment level with receiving adjuvant therapy for surgical patients was also analyzed. Recurrence-free survival and disease-specific survival were also assessed.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240113-8\"><jats:title>Results<\/jats:title><jats:p>The study population included 203 patients (mean [SD] age, 62 [10] years; 24 [12%] females and 179 males [88%]), 58 (29%) of whom were in the low, 73 (36%) in the moderate, and 72 (35%) in the high TTMV-HPV DNA fragment-level cohort. Compared to patients with cT0\/1 stage, those with cT2 stage and cT3\/4 stage had increased odds of higher TTMV-HPV DNA levels, with adjusted odds ratios (aORs) of 2.33 (95% CI, 1.24-4.46) and 2.51 (95% CI, 1.17-5.46), respectively. Compared to patients with cN0 stage, those with cN1 stage and cN2\/3 stage also had increased odds of higher TTMV-HPV DNA levels, with aORs of 4.26 (95% CI, 1.82-10.34) and 3.64 (95% CI, 1.46-9.36), respectively. In adjusted analysis of pretreatment PET-CT characteristics, total primary tumor plus nodal volume was associated with higher TTMV-HPV DNA levels, with an aOR of 1.04 (95% CI, 1.02-1.07). Among 94 surgical patients, no significant association was found between pretreatment fragment level and lymphovascular invasion, perineural invasion, pathologic T stage, number of positive nodes, or extranodal extension on pathological analysis of surgical specimen. No significant differences in recurrence-free survival or disease-specific survival were found.<\/jats:p><\/jats:sec><jats:sec id=\"ab-ooi240113-9\"><jats:title>Conclusion and Relevance<\/jats:title><jats:p>This cohort study found that higher pretreatment TTMV-HPV DNA fragment levels were associated with more advanced clinical staging and higher aggregate primary and cervical nodal volume on PET-CT results. Future studies are needed to explore how pretreatment fragment level may influence treatment decisions.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamaoto.2024.5549","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:02:55Z","timestamp":1741878175000},"page":"433","source":"Crossref","is-referenced-by-count":9,"title":["Pretreatment Liquid Biopsy and Clinicopathologic Features in HPV\u2212Associated Oropharyngeal Squamous Cell Carcinoma"],"prefix":"10.1001","volume":"151","author":[{"given":"Peter V.","family":"Cooke","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susmita","family":"Chennareddy","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel O.","family":"Kraft","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine","family":"Kappauf","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin S.","family":"Lam","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sida","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunal K.","family":"Sindhu","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael H.","family":"Berger","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rocco M.","family":"Ferrandino","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raksha","family":"Kulkarni","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Tang","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasrin","family":"Ghesani","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Diagnostic, Molecular and Interventional Radiology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Misiukiewicz","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Bakst","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marshall R.","family":"Posner","sequence":"additional","affiliation":[{"name":"Department of Hematology\/Oncology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric M.","family":"Genden","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond L.","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott A.","family":"Roof","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"ooi240113r1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.966899","article-title":"Current perspectives on recurrent HPV-mediated oropharyngeal cancer.","volume":"12","author":"Guo","year":"2022","journal-title":"Front Oncol"},{"issue":"36","key":"ooi240113r2","doi-asserted-by":"publisher","first-page":"4550","DOI":"10.1200\/JCO.2013.50.3870","article-title":"Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers.","volume":"31","author":"Chaturvedi","year":"2013","journal-title":"J Clin Oncol"},{"issue":"1","key":"ooi240113r3","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","article-title":"Human papillomavirus and survival of patients with oropharyngeal cancer.","volume":"363","author":"Ang","year":"2010","journal-title":"N Engl J Med"},{"key":"ooi240113r4","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.oraloncology.2019.06.021","article-title":"Standard of care vs reduced-dose chemoradiation after induction chemotherapy in HPV+ oropharyngeal carcinoma patients: the Quarterback trial.","volume":"95","author":"Misiukiewicz","year":"2019","journal-title":"Oral Oncol"},{"issue":"1","key":"ooi240113r5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1634\/theoncologist.2020-0303","article-title":"Optimizing treatment de-escalation in head and neck cancer: current and future perspectives.","volume":"26","author":"Rosenberg","year":"2021","journal-title":"Oncologist"},{"issue":"5","key":"ooi240113r6","doi-asserted-by":"publisher","first-page":"3668","DOI":"10.3390\/curroncol29050295","article-title":"De-escalation strategies for human papillomavirus-associated oropharyngeal squamous cell carcinoma-where are we now?","volume":"29","author":"Silver","year":"2022","journal-title":"Curr Oncol"},{"issue":"15","key":"ooi240113r7","doi-asserted-by":"publisher","first-page":"4682","DOI":"10.1158\/1078-0432.CCR-19-0211","article-title":"Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer.","volume":"25","author":"Chera","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ooi240113r8","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1200\/PO.18.00276","article-title":"Detection of early human papillomavirus-associated cancers by liquid biopsy.","volume":"3","author":"Damerla","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"11","key":"ooi240113r9","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1001\/jamaoto.2023.1937","article-title":"Performance of liquid biopsy for diagnosis and surveillance of human papillomavirus-associated oropharyngeal cancer.","volume":"149","author":"Ferrandino","year":"2023","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"4","key":"ooi240113r10","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1158\/1078-0432.CCR-21-3151","article-title":"Cell-free HPV DNA provides an accurate and rapid diagnosis of HPV-associated head and neck cancer.","volume":"28","author":"Siravegna","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"ooi240113r11","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1158\/1078-0432.CCR-21-2338","article-title":"Early HPV ctDNA kinetics and imaging biomarkers predict therapeutic response in p16+ oropharyngeal squamous cell carcinoma.","volume":"28","author":"Cao","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"10","key":"ooi240113r12","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer.","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"issue":"9","key":"ooi240113r13","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1093\/annonc\/mdy251","article-title":"Plasma HPV cell-free DNA monitoring in advanced HPV-associated oropharyngeal cancer.","volume":"29","author":"Hanna","year":"2018","journal-title":"Ann Oncol"},{"issue":"1","key":"ooi240113r14","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12967-020-02330-y","article-title":"Circulating HPV16 DNA may complement imaging assessment of early treatment efficacy in patients with HPV-positive oropharyngeal cancer.","volume":"18","author":"Rutkowski","year":"2020","journal-title":"J Transl Med"},{"issue":"1","key":"ooi240113r15","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1002\/ijc.33798","article-title":"Performance of oral HPV DNA, oral HPV mRNA and circulating tumor HPV DNA in the detection of HPV-related oropharyngeal cancer and cancer of unknown primary.","volume":"150","author":"Tanaka","year":"2022","journal-title":"Int J Cancer"},{"issue":"19","key":"ooi240113r16","doi-asserted-by":"publisher","first-page":"4292","DOI":"10.1158\/1078-0432.CCR-22-0562","article-title":"Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma.","volume":"28","author":"Berger","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ooi240113r17","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jmrs.720","article-title":"From planned neck dissection to PET response to circulating tumour DNA: changes in post-treatment assessment of HPV-driven oropharyngeal cancer.","volume":"71","author":"Post","year":"2024","journal-title":"J Med Radiat Sci"},{"issue":"19","key":"ooi240113r18","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1002\/cncr.29538","article-title":"Circulating human papillomavirus DNA as a marker for disease extent and recurrence among patients with oropharyngeal cancer.","volume":"121","author":"Dahlstrom","year":"2015","journal-title":"Cancer"},{"issue":"5","key":"ooi240113r19","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1001\/jamaoto.2024.0350","article-title":"Preoperative circulating tumor HPV DNA and oropharyngeal squamous cell disease.","volume":"150","author":"Lam","year":"2024","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"issue":"12","key":"ooi240113r20","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1001\/jamaoto.2022.3282","article-title":"Association of pretreatment circulating tumor tissue-modified viral HPV DNA with clinicopathologic factors in HPV-positive oropharyngeal cancer.","volume":"148","author":"Rettig","year":"2022","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"ooi240113r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.04.007","article-title":"Clinical utility of circulating tumor DNA in Patients with advanced KRAS(G12C)-mutated NSCLC treated with sotorasib.","author":"Ernst","year":"2024","journal-title":"J Thorac Oncol"},{"issue":"7","key":"ooi240113r22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.25332","article-title":"Association of circulating tumor DNA testing before tissue diagnosis with time to treatment among patients with suspected advanced lung cancer: the ACCELERATE nonrandomized clinical trial.","volume":"6","author":"Garc\u00eda-Pardo","year":"2023","journal-title":"JAMA Netw Open"},{"key":"ooi240113r23","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2024.106874","article-title":"Utility of TTMVV-HPV DNA in resolving indeterminate findings during oropharyngeal cancer surveillance.","volume":"155","author":"Roof","year":"2024","journal-title":"Oral Oncol"},{"issue":"4","key":"ooi240113r24","doi-asserted-by":"publisher","first-page":"725","DOI":"10.3390\/diagnostics13040725","article-title":"Analytical validation of NavDx, a cfDNA-based fragmentomic profiling assay for HPV-driven cancers.","volume":"13","author":"Gunning","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"30","key":"ooi240113r25","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1200\/JCO.2014.55.1937","article-title":"Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.","volume":"32","author":"Fakhry","year":"2014","journal-title":"J Clin Oncol"},{"key":"ooi240113r26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.oraloncology.2018.09.018","article-title":"Survival for HPV-positive oropharyngeal squamous cell carcinoma with surgical versus nonsurgical treatment approach: a systematic review and meta-analysis.","volume":"86","author":"Sinha","year":"2018","journal-title":"Oral Oncol"},{"issue":"14","key":"ooi240113r27","doi-asserted-by":"publisher","first-page":"3600","DOI":"10.3390\/cancers13143600","article-title":"Signed in blood: circulating tumor DNA in cancer diagnosis, treatment and screening.","volume":"13","author":"Adashek","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ooi240113r28","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/cncr.34109","article-title":"Cell-free human papillomavirus DNA kinetics after surgery for human papillomavirus-associated oropharyngeal cancer.","volume":"128","author":"O\u2019Boyle","year":"2022","journal-title":"Cancer"},{"issue":"16","key":"ooi240113r29","doi-asserted-by":"publisher","first-page":"6066","DOI":"10.1200\/JCO.2024.42.16_suppl.6066","article-title":"Can TTMVV clearance predict recurrence in HPV HNSCC?","volume":"42","author":"Misiukiewicz","year":"2024","journal-title":"J Clin Oncol"},{"key":"ooi240113r30","doi-asserted-by":"publisher","DOI":"10.1200\/PO.22.00494","article-title":"Clearance profile of circulating tumor human papillomavirus DNA during radiotherapy predicts clinical outcomes in human papillomavirus-related oropharyngeal cancer.","volume":"7","author":"Tanaka","year":"2023","journal-title":"JCO Precis Oncol"}],"container-title":["JAMA Otolaryngology\u2013Head &amp; Neck Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/articlepdf\/2831120\/jamaotolaryngology_cooke_2025_oi_240113_1746216362.53855.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T15:01:19Z","timestamp":1746716479000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaotolaryngology\/fullarticle\/2831120"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,1]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoto.2024.5549","relation":{},"ISSN":["2168-6181"],"issn-type":[{"value":"2168-6181","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,1]]}}}